Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
Sign Up to like & getrecommendations! Published in 2019 at "Rheumatology"
DOI: 10.1093/rheumatology/key267
Abstract: OBJECTIVES Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the… read more here.
Keywords: spa; emergence severe; following successful; disease ... See more keywords